Product Description
Mechanisms of Action: 5-HT3 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dynogen
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Constipation|Irritable Bowel Syndrome
Phase 2: Irritable Bowel Syndrome|Constipation|Esophagitis, Peptic|Gastroesophageal Reflux
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00215566 |
DDP733-04-007 | P2 |
Completed |
Irritable Bowel Syndrome|Constipation |
None |
2019-03-21 |
Treatments |
|
NCT01161602 |
Pumo-10-001 | P2 |
Completed |
Esophagitis, Peptic|Gastroesophageal Reflux |
None |
2019-03-19 |
||
NCT00547469 |
DDP733-07-010 | P3 |
Unknown status |
Constipation|Irritable Bowel Syndrome |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|